Connection

Nathan Dolloff to Xenograft Model Antitumor Assays

This is a "connection" page, showing publications Nathan Dolloff has written about Xenograft Model Antitumor Assays.
  1. Discovery platform for inhibitors of IgH gene enhancer activity. Cancer Biol Ther. 2019; 20(4):571-581.
    View in: PubMed
    Score: 0.143
  2. Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Sci Transl Med. 2011 Jun 08; 3(86):86ra50.
    View in: PubMed
    Score: 0.085
  3. Syrbactin proteasome inhibitor TIR-199 overcomes bortezomib chemoresistance and inhibits multiple myeloma tumor growth in vivo. Leuk Res. 2020 01; 88:106271.
    View in: PubMed
    Score: 0.038
  4. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013 Feb 06; 5(171):171ra17.
    View in: PubMed
    Score: 0.024
  5. Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. Cancer Biol Ther. 2011 Aug 01; 12(3):229-38.
    View in: PubMed
    Score: 0.022
  6. Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer. Cancer Biol Ther. 2011 Aug 01; 12(3):239-51.
    View in: PubMed
    Score: 0.022
  7. Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3? and CDK1. Cancer Res. 2011 Aug 01; 71(15):5265-75.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.